{"abstract":"The National Heart, Lung, and Blood Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive, Sublicensable Patent License to consolidate co-owned rights to the inventions and the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice to The Children's Medical Research Institute, having a place of business in Westmead NSW, Australia.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/06/29/2021-13826.html","cfr_references":[],"citation":"86 FR 34246","comment_url":null,"comments_close_on":"2021-07-14","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license that are received by the National Heart, Lung, and Blood Institute Office of Technology and Development on or before July 14, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-13826","effective_on":null,"end_page":34246,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/06/29/2021-13826.xml","html_url":"https://www.federalregister.gov/documents/2021/06/29/2021-13826/prospective-grant-of-an-exclusive-patent-license-adeno-associated-virus-polynucleotides-polypeptides","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-13826?publication_date=2021-06-29","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-06-29/2021-13826/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":130,"last_updated":"2026-08-24 06:15:07 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-06-29/pdf/2021-13826.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-13826.pdf?1624884333","publication_date":"2021-06-29","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/06/29/2021-13826.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T22:31:49Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":34246,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Adeno-Associated Virus Polynucleotides, Polypeptides and Virions","toc_doc":"Adeno-associated virus polynucleotides, polypeptides and virions","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}